CD4 and neoplasm: Then, we revealed that PCSK9i could elevate MHC-II+ and antigen-presenting CD103+ DC proportions in spleen cells, sensitize tumor cells to be killed by T cells, and indirectly activate both CD4+ and CD8+ T cells in vitro.